A5023659191- Hematopoietic Stem Cell Transplantation
- Antifungal resistance and susceptibility
- Immune Cell Function and Interaction
- Fungal Infections and Studies
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Blood disorders and treatments
- T-cell and B-cell Immunology
- Mycobacterium research and diagnosis
- Immunotherapy and Immune Responses
- Renal Transplantation Outcomes and Treatments
- Virus-based gene therapy research
- Transplantation: Methods and Outcomes
- Acute Lymphoblastic Leukemia research
- HIV Research and Treatment
- Cystic Fibrosis Research Advances
- Mesenchymal stem cell research
- Sepsis Diagnosis and Treatment
National Institutes of Health
2015-2025
National Institute of Allergy and Infectious Diseases
1997-2025
National Institutes of Health Clinical Center
2004-2023
Mayo Clinic Hospital
2018-2023
Mayo Clinic
2023
Jacksonville University
2023
University of California, Irvine
2023
WinnMed
2017-2021
Mayo Clinic in Florida
2017-2021
Office of Infectious Diseases
2021
We investigated the combination of lymphodepleting chemotherapy followed by adoptive transfer autologous tumor reactive lymphocytes for treatment patients with refractory metastatic melanoma.Thirty-five melanoma, all but one disease to high-dose interleukin (IL) -2 and many progressive after chemotherapy, underwent conditioning two days cyclophosphamide (60 mg/kg) five fludarabine (25 mg/m(2)). On day following final dose fludarabine, received cell infusion tumor-reactive, rapidly expanded...
Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from transplant donor. DLIs frequently not effective at eradicating and graft-versus-host disease, a potentially lethal immune response against normal recipient tissues.
The Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidelines for ancillary therapy supportive care in chronic graft-versus-host disease (GVHD), including treatment symptoms recommendations patient education, preventive measures, appropriate follow-up; (2) provide the prevention management of infections other common complications GVHD; (3) highlight areas with greatest need clinical research. definition “ancillary care” embraces most frequent...
The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary Therapy and Supportive Care Working Group to support clinical research trials in chronic graft-versus-host disease (GVHD). Topics covered that inaugural effort included prevention management infections common complications GVHD, as well for patient education appropriate follow-up. Given new literature has emerged during past 8 years, we made further organ-specific refinements these...
The virus-specific CD8+ T cell responses of 21 HIV-infected patients were studied including a unique cohort long-term nonprogressors with low levels plasma viral RNA and strong proliferative to HIV Ags. HIV-specific by combination standard cytotoxic (CTL) assays, MHC tetramers, TCR repertoire analysis. frequencies cells specific the majority gene products measured flow cytometric detection intracellular IFN-gamma in response HIV-vaccinia recombinant-infected autologous B cells. Very high...
As part of a prospective natural history cohort study voriconazole toxicity, we describe the characteristics 12 72 voriconazole-treated patients who experienced hallucinations from March 2006 through November 2007. Hallucinations associated with use are not uncommon. Doctors should be aware this complication, and recipients drug reassured that an effect drug.
West Nile virus, a member of the family Flaviviridae, has spread throughout United States. With more than 9000 cases and 200 deaths in 2003, virus become most common cause viral encephalitis several states. is zoonosis. The life cycle includes mainly birds as hosts mosquitoes vectors. Humans are accidental hosts, insufficient to support because low-grade, transient viremia. However, human-tohuman transmission through blood, organ transplantation, lactation been documented. frequency severe...
One-half of bone-marrow transplant (BMT) and stem-cell recipients have reactivation latent human herpesvirus (HHV)-6 2–4 weeks after transplant. Although the detection viral DNA, RNA, antigen in brain material confirmed active HHV-6 variant B infection, peak loads cerebrospinal fluid (CSF) serum occurred before death decreased to low levels or at autopsy. All autopsy samples consistently demonstrated infection hippocampus. Astrocytic cells positive for provided support an HHV-6-specific...
We treated 14 patients with GATA2 deficiency using a nonmyeloablative allogeneic hematopoietic stem cell transplantation regimen. Four received peripheral blood cells from matched related donors (MRD), 4 unrelated (URD), umbilical cord (UCB), and 2 bone marrow haploidentical donors. MRD URD recipients conditioning 3 days of fludarabine 200 cGy total body irradiation (TBI). Haploidentical donor UCB cyclophosphamide additional along cGY TBI. MRD, URD, tacrolimus sirolimus for...
To describe the presentation and management of encephalitis due to human herpes 6 virus (HHV-6) in patients who underwent allogeneic hematopoietic stem cell transplant (alloHSCT), via retrospective chart review.Of 243 alloHSCT at NIH Clinical Center during 2009 2011, we retrospectively analyzed 9 diagnosed with HHV-6 post-alloHSCT.Eight men 1 woman (aged 19-60 years) met diagnostic criteria for study inclusion. The median time from HSCT initial symptoms was 21 days. All presented altered...
Between 2004 and 2010, 189 adult patients were enrolled on the National Cancer Institute's cross-sectional chronic graft-versus-host disease (cGVHD) natural history study. Patients evaluated by multiple scales outcome measures, including 2005 Institutes of Health (NIH) Consensus Project cGVHD severity scores. The purpose this study was to assess validity NIH scoring variables as determinants in severely affected efforts standardize clinician evaluation staging cGVHD. Out enrolled, 125 met...